Skip to content

Risk Assessment Strategies in Pulmonary Embolism

Risk Stratification in Pulmonary Embolism

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04327960
Enrollment
100
Registered
2020-03-31
Start date
2021-09-01
Completion date
2023-10-01
Last updated
2020-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Embolism

Brief summary

The aim of this study is to evaluate different scores of risk assessment in patients with pulmonary embolism. This study aim to compare the accuracy of these scores in predicting mortality during hospital admission.

Detailed description

Pulmonary embolism (PE) is a potentially life-threatening cardiovascular emergency with a high mortality rate.Approximately 1% of all hospitalized patients and 10% of all in-hospital mortalities are PE related. Adding to this, acute PE is linked to comparatively high (≥13%) short-term mortalities that occur either in hospital or within 30 days. Some studies have demonstrated that PE may indicate increased 1-year mortality rates up to 25%,,. Therefore, PE is considered a potentially fatal disease, although patients who escape a PE-related death are still endangered by hematologic mishaps, especially recurrence of VTE and/or PE, or on the contrary, serious hemorrhage5. Risk stratification of patients with acute PE is mandatory for determining the appropriate therapeutic management approach. Risk classification of PE can discriminate low-risk patients, who can be medicated as outpatients, from others at high risk, in whom a profit from intensive care unit admission or even in-hospital thrombolytic therapy is expected.

Interventions

DIAGNOSTIC_TESTCardiac troponin (cTn)

Cardiac troponin (cTn) will be measured with the Dimension RxL-HM analyzer .The one-step enzyme immunoassay is based on cTn specific monoclonal antibodies, performed on a separate module of the analyzer, assay-time is 17 minutes.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

\- All patients will be subjected to the following: 1. Complete history taking and clinical examination. 2. Chest x-ray 3. ECG and echocardiography. 4. Arterial blood gases. 5. Multislice CT angiography of the chest. 6. Laboratory tests and biomarkers.

Exclusion criteria

* 1- Patients with unexpected or accidental diagnosis of PE (patients undergoing diagnostic tests for another suspected disease. 2- Patients with acute left heart failure or acute respiratory failure responsible for symptoms. 3- Patient with recurrent PE (only the first event was included in the analysis).

Design outcomes

Primary

MeasureTime frameDescription
Pulmonary embolism-related deathBaselineApproximately 1% of all hospitalized patients and 10% of all in-hospital mortalities are PE related. Adding to this, acute PE is linked to comparatively high (≥13%) short-term mortalities that occur either in hospital or within 30 days

Secondary

MeasureTime frameDescription
hospital stay, need for ICU admission, need for mechanical ventilation or cardiopulmonary resuscitation or home dischage.Baselinepatients who escape a PE-related death are still endangered by hematologic mishaps, especially recurrence of VTE and/or PE, or on the contrary, serious hemorrhage

Contacts

Primary ContactMariam Louiz, Master
mariamlouiz1990@gmail.com+2012885523082

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026